Sobi™ publishes its report for the third quarter 2017
Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces its results for the third quarter 2017. Total revenues amounted to SEK 1,601 M, an increase of 37 per cent. Product sales amounted to SEK 1,459 M, an increase of 45 per cent. Elocta® sales were SEK 417 M and Alprolix® sales were SEK 98 M. Business highlights Q3 2017 · Focus on future growth · 37 per cent sales growth in the quarter · 601 per cent product sales growth in Haemophilia · Solid development for Orfadin® 20 mg and oral suspension in the US Financial summary Q3 2017 (Q3 2016) ·